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Marked proliferation of rat hepatic peroxisomes is observed after treatment with a new potent hypolipidemic drug BM 15766, as well as after 
bezafibrate. Whereas the relative specific activity of the peroxisomai fatty acid /?-oxidation system is not affected by BM 15766 it is significantly 
increased after bezafibrate. This is also confirmed by immunoblot analysis of individual p-oxidation enzymes in highly purified peroxisome fractions. 
These observations uggest hat peroxisome proliferation and the induction of the fatty acid /?-oxidation are regulated separately. 
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1. INTRODUCTION 
The fatty acid P-oxidation system in rat liver perox- 
isomes (PO) is induced by a variety of hypofipidemic 
drugs which simultaneously give rise to PO prolifera- 
tion [ 11. In most previous studies, the PO proliferation 
has been closely associated with marked induction of 
the &oxidation of long-chain fatty acids [2]. Indeed, 
the distinct elevation of an 80 kDa protein, which is 
most probably identical with the bifunctional protein 
(hydratase-dehydrogenase) has been used as a specific 
marker for the proliferation of PO 121. Since the car- 
cinogenicity of PO proliferators observed in rodents 
has been attributed to the increased activity of the fatty 
acid P-oxidation system and the possible oxidative 
damage of DNA [3], the search for hypolipidemic 
drugs which do not induce the PO p-oxidation system 
has been intensified. In this study we present evidence 
that a new potent hypolipidemic drugs, BM 15766 [4], 
induces marked proliferation of liver PO widhout 
significant elevation of then-o~dation system in highly 
purified PO fractions. These findings suggest that PO 
proliferation and the induction of the &oxidation en- 
zymes are regulated separately. 
dard laboratory diet and water ad libitum, were used. For 
biochemical and morphological studies groups of 5 animals each were 
administered by gastric intubation for 14 days either 50 or 75 mg/kg 
per day benaafibrate (2- [4-[2-(4-chlorobenzamide)ethyl]phenoxy ] -2- 
methylpropionic acid) or 75 mg/kg per day BM 15766 (4-l 2-[4-(4- 
chlorocinnamyl)pi~razin- 1 yl]ethyI 1 benzoic acid), suspended in 
methyl~llulose. The controt group received the corresponding 
amount of methylcellulose. The triglycerides and total sterol content 
of the serum were determined [S] in blood samples obtained from the 
retrooccular plexus after 7 and 14 days of treatment. 
2.2. Morphology 
Animals were anesthetized with chtoralhydrate and the livers were 
perfused via the portal vein with a fixative containing 0.25% 
ghrtaraldehyde, 2% sucrose in 0.1 M Pipes buffer, pH 7.4. For the 
c~~hernic~ visualization of PO, 80~m tissue sections were in- 
cubated in alkaline 3,3’~ia~nob~~dine 161, post-fixed with reduc- 
ed 0~04 and embedded in Epon. 
2.3. Isolation of peroxisomes (PO) 
Rat livers were perfused for 5 min with physiological saline 
through the portal vein. After homogenization an enriched PO frac- 
tion (D-fraction) was isolated as described before [7]. Highly purified 
PO fractions (>98%) were obtained by Met&amide-gradient cen- 
trifugation [7]. 
2.4. Enzyme activity determinations 
Carnitine acetyltransferase, cataiase and the cyanide insensitive 
fatty acid&oxidation activity were measured as described [7,8]. Pro- 
tein was determined by Bradford [9] or Lowry et al. [lo] procedures. 
2. MATERIALS AND METHODS 
2.1. Animals 
2.5. Immunobtotting 
Mate Sprague-Dawley rats, weighing 200-250 g, kept on a stan- 
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Antibodies against PO proteins were raised in rabbits and their 
specificity was assessed by immunoblotting as described before fl I]. 
Equal amounts of protein [9] from highly purified PO fractions were 
subjected to SDS-PAGE (12.5% gel, 9 x 5 x 0.1 cm), using a 
microslab electrophoresis apparatus. After electrotransfer onto 
nitrocellulose, the blots were immunostained as described previously 
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[l 11. The immunoblots were subjected to quantitative analysis using 
a television-based image analyzer [ll]. The same gels used for im- 
munoblotting were stained with silver after electrotransfer to assess 
the overall alterations of PO proteins 112). 
3. RESULTS 
Whereas no differences in body weight gains were 
observed, the relative liver weights were increased to 
114% with BM 15766 and 145% with 50 mg/kg per day 
bezafibrate. 
3.1. Serum lipids 
Treatment either with BM 15766 or bezafibrate 
reduced the serum triglyceride and sterol levels (Table 
I). 
3.2. Morphology 
Marked proliferation of PO was observed in 1 pm 
liver sections, stained for the cytochemical localization 
of catalase, after both bezafibrate and BM 15766. 
Whereas PO proliferation was more pronounced in 
pericentral hepatocytes after BM 15766, it was 
uniformly distributed in the liver lobule in bezafibrate- 
treated rats (Fig. 1). By electron microscopy the pro- 
liferation of PO in all treated groups was confirmed. 
Moreover, clustering of enlarged angular PO with pro- 
liferation of SER was observed in pericentral 
hepatocytes of BM 15766-treated animals (Fig. Ic). 
3.3, Enzyme activities 
Whereas carnitine acetyltransferase activity in total 
liver homogenates of bezafibrate-treated rats was in- 
creased by a factor of 10.5 (controls: 9.2 f 0.1 mU/mg 
protein, [lo]), it showed only a minor elevation 
(l.Cfold) after BM 15766. The catalase activity (U/g 
liver) in D-fractions was increased significantly both in 
BM 15766- and 50 mg/kg per day bezafibrate-treated 
animals (Table II). Its relative specific activity (RSA) 
(RSA is defined as the specific enzyme activity (U/mg 
protein) in the enriched PO-fraction divided by that in 
the total homogenate), however, was slightly elevated 
in the BM 15766-treated group but was not significantly 
changed after 50 mg/kg per day bezafibrate, and was 
reduced by 40% in the group treated with 75 mg/kg per 
day bezafibrate. The cyanide insensitive fatty acid ,& 
oxidation activities in D-fractions were increased in all 
experimental groups, with bezafibrate exerting a much 
stronger effect than BM 15766 (Table II). The cor- 
responding RSA values, however, were significantly in- 
creased (2.2-fold) only in bezafibrate-treated animals 
(50 mg/kg per day), with BM 15766 showing no signifi- 
cant change. Whereas the ratio of activities of fatty 
acid p-oxidation to catalase was not significantly 
altered after BM 15766 it was markedly increased in 
bezafibrate-treated animals (Table II). 
3.4. SDS-gels and irnmunoblots 
Whereas the polypeptide pattern of silver-stained 
SDS-gels from highly purified PO fractions of control 
and BM 15766-treated animals was almost identical, 
preparations from bezafibrate-treated animals ex- 
hibited marked changes in protein composition of PO 
(Fig. 2). Thus, a marked increase in all &oxidation en- 
zyme bands and a decrease in the catalase band was 
noted (Fig. 2). This impression was confirmed in im- 
munoblots and their quantitative densitometric 
analyses (Figs 3-5). As shown in Fig. 3, acyl-CoA ox- 
idase was substantially increased in PO of bezafibrate- 
treated animals, although at different rates with respect 
to the individual subunits A-C. On the other hand, only 
subunit C of BM 15766-treated rats showed an increase 
with a concomitant reduction of subunits A and B. 
Bezafibrate treatment further increased the bifunc- 
tional protein drastically (Fig. 4), whereas the control 
and BM 15766 bands showed essentially the same inten- 
sity. Whereas the PO thiolase (Fig. 5) was only slightly 
changed with BM 15766, it was markedly increased 
after bezafibrate. The catalase protein was reduced 
more intensely after bezafibrate than BM 15766 treat- 
ment (Fig. 6). 
Table I 
Effects on serum lipids after 7 and 14 days of treatment with BM 15766 and 
bezafibrate (75 mg/kg) in comparison to control values 
Triglycerides (mg/dl) Total sterols (mg/dl) 
7 days 14 days I days 14 days 
Control 146.2 f 12.67 155.1 f 11.22 80.14 f 2.61 82.43 + 3.83 
(100%) (100%) (IOOVO) (100%) 
BM 15766 80.9 * 7.59 79.2 + 4.84 33.87 f 1.09 24.44 f 1.11 
(55.3%) (51%) (42.3%) (29.6%) 
Bezafibrate 59.1 f 6.46 13.4 + 9.95 56.43 f 2.77 53.71 f 4.02 
(40.4%) (47.3%) (70.4%) (65.2%) 
n = 5; for all treated groups P < 0.005 
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Fig. 1. Sections of rat liver stained for visualization of PO. (a) Light micrograph of a control rat with normal distribution of PO around a central 
vein (CV). Bar = 25 pm. (b) Liver of a rat treated with BM 15766 showing marked pericentral proliferation of PO. Bar = 25 pm. (c) Electron 
micrograph of a centrilobular hepatocyte from BM 15766-treated animals. Note marked proliferation of PO and smooth endoplasmic reticulum 
(SER). Bar = 800 nm. 
4. DISCUSSION 
Treatment with both bezafibrate and BM 15766 
reduced significantly the serum lipids (Table I) and in- 
duced marked proliferation of PO. The proliferation of 
peroxisomes was also adduced by the increased ac- 
tivities of the PO marker enzyme catalase and the 
cyanide insensitive fatty acid &oxidation system in 
enriched PO fractions (Table II). The corresponding 
RSA values, however, indicate an increase of the ,& 
oxidation system only after bezafibrate but not with 
BM 15766. This is also clearly demonstrated by the 
ratios of the fatty acid &oxidation activity to catalase, 
which was markedly elevated only after bezafibrate. 
These results were confirmed by SDS-PAGE and im- 
munoblot analysis of highly purified PO fractions. All 
together they demonstrate that BM 15766 induces PO 
proliferation with only minor effects on the polypep- 
tide composition of the organelle. This finding implies 
that PO proliferation is not necessarily accompanied by 
7 
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Table II 
Effects on peroxisomal enzymes in enriched peroxisomal fractions 
(D-fractions) after 14 days of treatment with BM 15766 and 
bezafibrate (50 mg/kg) 
Control BM 15766 Bezafibrate 
Catalase 
(U/g liver) 1.91 f 0.13 2.80 + O.iO** 3.06 + 0.62** 
&oxidation 
(U/g liver) 18.41 f 1.39 25.39 + 1.04** 56.09 -I: 8.50** 
Catalase (RSA) 3.68 + 0.29 5.29 rt 0.38* 3.07 It 0.33 
p-oxidation 
(RSA) 2.76 f 0.16 3.05 i 0.17 5.98 f 0.38** 
&ox/Cat (RSA) 0.75 0.58 1.95** 
n = 5; * P < 0.05; ** P < 0.005 
kD 
66’ 
24 ’ 
18.4* 
F I 
 ^ x 
0 HYDRATASE 
,HYDRATASE 
_ AOX- A 
-CATALASE 
-AOX- B 
--JHIOLASE 
I-AOX-C 
simuIt~eous induction of the &oxidation enzymes and 
that these two phenomena may be regulated in- 
dependently. Whereas the main pharmacologic effect 
of BM I5766 is exerted by the competitive inhibition of 
the 7-DHC-A7-reductase in cholesterol biosynthesis [4], 
the exact mode of action of bezafibrate and related 
substances is still subject of intensive research [131. An 
important enzyme system influencing the substrate 
flow to the PO &oxidation is the cytochrome P450 
IVAl-system. Cytochrome P450 IVAl catalyzes the w- 
hydroxylation of fatty acids and its activity is strongly 
increased during treatment with hypolipidemic agents 
[ 141. The w-hydroxyl fatty acids are further oxidized in 
the cytosol to dicarboxylic acids, which can only be 
degraded in PO and may lead to the drastic increase of 
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Fig. 2. SDS-PAGE of highly purified PO fractions (3 /tg protein) obtained from controls, and BM 15766 as well as bezafibrate-treated rat livers. 
After the electrotransfer of polypeptides, the gel was stained with silver [12]. Standard molecular weight markers are indicated on the left and 
PO &oxidation enzymes, as well as catalase on the right. Note the marked increase of ,&oxidation polypeptides and the reduction of catalase 
after bezafibrate treatment. 
Figs 3-6. Immunoblots of highly purified PO-fractions from control and treated animals. The densitometric values relative to control are shown 
in parentheses. Fig. 3: Acyl-CoA oxidase (3 ,ug protein). Three subunits with molecular masses of 72, 52 and 20.5 kDa (A, B and C respectively) 
are identified, showing increased intensities (A: 211%; B: 120%; C: 265%) in bezafibrate-treated animals. Note also the slightly more intense 
subunit C (175%) with concomitant decrease of subunits A (7670) and B (86%) after BM 15766 treatment. Fig. 4: Bifunctional protein (hydratase- 
dehydrogen~e) (1.5 ~(g of protein at left and 4 pg protein at right - stars): Bezafibrate induced drastically this protein (20-fold), while BM 15766 
showed little effect. Fig. 5: Thiolase (1.5 pg protein). Note the marked increase with bezafibrate (650%) and the minor effect of BM 15766 (13OVo). 
Fig. 6: Catalase (3 pg protein). Both treated groups show reduction with bezafibrate being more pronounced than BM 15766. 
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the PO &oxidation system during fibrate treatment in 
rodents [ 14,151. The induction of cytochrome P450 
IVAl-system after treatment with hypolipidemic drugs 
correlates with the hepatomegaly and the increase in 
carnitine acetyl-transferase activity [ 151. It is of interest 
that BM 15766 does not give rise to marked 
hepatomegaly or elevation of the carnitine acetyl- 
transferase activity, a finding which is consistent with 
the lack of induction of the PO P-oxidation enzymes in 
highly purified PO-fractions. It has been proposed that 
induction of PO proliferation is mediated by am- 
phipathic carboxylic acid derivatives and that the car- 
boxylic function is necessary for the proliferation of 
PO, whereas changes in the ‘hydrophobic backbone’ of 
the compounds may only vary the efficacy of PO pro- 
liferation [ 161. Since BM 15766 is an amphipathic om- 
pound with a carboxylic group it seems to fulfill the 
requirements necessary for the induction of PO pro- 
liferation. In contrast to other PO proliferators, 
however, BM 15766 does not induce the PO ,& 
oxidation enzymes. This suggests that additional fac- 
tors such as interaction with other enzyme systems of 
liver lipid metabolism, changes in substrate flow to fat- 
ty acid or glycerolipid synthesis, and overload of the 
liver mitochondrial &oxidation system with fatty acid 
derivatives may be necessary to induce the PO ,8- 
oxidation system. Since recent studies in our laboratory 
indicate that BM 15766 treatment induces an elevation 
of the 70 kDa integral PO membrane protein [17] 
without marked alterations of the &oxidation enzymes 
and other PO matrix proteins, this drug could provide 
a suitable tool to elucidate the exact mechanism of PO 
proliferation and 
carcinogenesis. 
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